ArticleClinical journal of gastroenterology2012
Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases.
Article in Clinical journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Regorafenib Induced Interstitial Pneumonia in a Patient With Refractory Rectal Cancer.Respirology case reports · 2025Article
- Regorafenib pulmonary toxicity: A case of cavitary lung disease and ARDS treated with infliximab.Respiratory medicine case reports · 2025Article
- Blocking autophagy with chloroquine aggravates lipid accumulation and reduces intracellular energy synthesis in hepatocellular carcinoma cells, both contributing to its anti-proliferative effect.Journal of cancer research and clinical oncology · 2022Article
- Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.Internal medicine (Tokyo, Japan) · 2022Article
- Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases.Journal of thoracic disease · 2020Review
- Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.BMJ case reports · 2020Article
- Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.Current fungal infection reports · 2019Article
- Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.Clinical journal of gastroenterology · 2019Article
- A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.BMC cancer · 2016Article
- Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report.Oncology letters · 2015Article
- Treatment for hepatocellular carcinoma in elderly patients: a literature review.Journal of Cancer · 2013Review
- Interstitial Lung Disease Induced by Pazopanib Treatment.Internal medicine (Tokyo, Japan)Article
- Jianpi-Huayu Formula Inhibits Development of Hepatocellular Carcinoma by Regulating Expression of miR-602, Which Targets theIntegrative cancer therapiesArticle
- Sorafenib-Induced Capillary Leak Syndrome.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about acute interstitial pneumonia (AIP) induced by sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC). Here, we present three patients with advanced HCC who developed AIP during sorafenib therapy, with fatal complications in two cases. Case 1 was a 76-year-old man who developed dyspnea. Chest CT showed interstitial pneumonia. Sorafenib was discontinued immediately, and prednisolone was started. His pneumonia resolved. A drug-induced lymphocyte stimulation test for sorafenib was positive. Case 2 was a 75-year-old man and case 3 was a 77-year-old man, both of whom developed high-grade fever and hypoxemia during sorafenib therapy, and were diagnosed with AIP. In spite of high-dose steroid therapy, their respiratory failure worsened and both patients died. In all three cases, serum KL-6 or surfactant protein D concentrations were elevated, and blood and sputum cultures did not grow pathogens. All three patients were smokers with restrictive lung disease on preoperative respiratory function testing, but did not have respiratory symptoms before sorafenib therapy. The clinical features of these three cases suggest that male gender, older age, smoking history, and lung disease are associated with acute sorafenib-induced AIP in patients with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.